Article
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
European journal of cancer (Oxford, England : 1990) - 1 May 2021
Tanaka Kentaro, Asahina Hajime, Kishimoto Junji, Miyata Yoshihiro, Uchida Takahiro, Watanabe Kana, Hamai Kosuke, Harada Taishi, Tsubata Yukari, Sugawara Shunichi, Kobayashi Kunihiko, Sugio Kenji, Oizumi Satoshi, Okamoto Isamu
Abstract excerpt
BACKGROUND: Osimertinib is now a standard treatment for patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). We here investigated whether the combination of osimertinib with cytotoxic chemotherapy might hold additive efficacy, as well as tolerability. PATIENTS AND METHODS: We conducted an open-label randomised phase 2 study to evaluate osimertinib and carboplatin-pemetrexed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.